JFL(SH:600901) 梧桐树下V·2025-04-30 15:09Core Viewpoint - The article discusses the regulatory actions taken by the Shenzhen Stock Exchange against Diga Pharmaceutical Group Co., Ltd. and its associated parties due to various violations during the IPO application process, leading to the termination of their IPO review. Group 1: Regulatory Actions - The Shenzhen Stock Exchange issued three written warning letters and three public criticism decisions on April 30, 2025, against Diga Pharmaceutical and related parties [2][3] - The IPO application for Diga Pharmaceutical was accepted on June 16, 2023, but was terminated on June 12, 2024, due to the withdrawal of the application by the issuer and the sponsor [27] Group 2: Violations Identified - Diga Pharmaceutical and its key executives failed to fully disclose independence flaws and rectification measures, as well as internal control deficiencies related to sales, procurement, and inventory management [4][8] - The sponsor, Minsheng Securities, did not adequately scrutinize the issuer's independence issues and internal control irregularities, leading to inaccurate verification opinions [5][17] - The law firm, Shanghai Zechang, and the accounting firm, Tianjian, also failed to conduct thorough checks on the issuer's independence and internal control issues, resulting in regulatory warnings [19][21] Group 3: Specific Issues - The issuer prioritized purchasing from suppliers controlled by the actual controller, which raised concerns about independence and internal control [8][19] - There were discrepancies in the accounting treatment of returns, with the issuer misclassifying a return as a post-balance sheet adjustment, which should have been reflected in 2020 instead of 2019 [10][24] - The issuer's internal controls were found to be inadequate, with missing documentation and improper handling of sales and inventory management [9][15]